Seymour JF, Kipps TJ, Eichhorst B, et al. MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting and Exposition 2018, abstract 184.
Acalabrutinib, venetoclax en obinutuzumab bij gerecidiveerde CLL
jun 2024 | Leukemie